Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027300 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
NCT00027300 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 900 participants.
The verdict
NCT00027300, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
Interventions
- DRUG Placebo
- DRUG Natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2001-11 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027300
The ClinicalTrials.gov registry entry for NCT00027300 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00027300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027300 about?
NCT00027300 is a clinical study titled "Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis". The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream i...
What is the current status of trial NCT00027300?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2001-11. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00027300?
The interventions under investigation include: Placebo (DRUG), Natalizumab (DRUG).
Who is sponsoring clinical trial NCT00027300?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.